|
May 6
|
The Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes
|
|
May 6
|
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
|
|
Apr 22
|
With 85% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing
|
|
Apr 22
|
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics
|
|
Apr 21
|
11 Best Low Price Pharma Stocks To Invest In
|
|
Apr 19
|
20 Countries with the Highest Cancer Survival Rates in the World
|
|
Apr 18
|
Astrazeneca (AZN) Could Be a Great Choice
|
|
Apr 16
|
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
|
|
Mar 26
|
UPDATE 1-China to speed up 'new productive forces', vice president says
|
|
Mar 25
|
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know
|
|
Mar 25
|
31 European Countries That Offer Citizenship by Descent
|
|
Mar 25
|
German industry sceptical of China's vow to treat foreign firms equally
|
|
Mar 25
|
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
|
|
Mar 25
|
ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
|
|
Mar 22
|
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
|
|
Mar 22
|
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
|
|
Mar 21
|
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
|
|
Mar 21
|
UPDATE 2-Merck combination treatment for lung cancer fails late-stage study
|
|
Mar 20
|
UPDATE 1-GSK to cap out-of-pocket inhaler costs in US
|